Vaxcyte EVP, COO Jim Wassil sells $1.56m in shares
Vaxcyte's EVP and COO Jim Wassil sold 18,000 shares for $1.56m at $86.74 each on Oct 5, 2026, and acquired 18,000 shares via option exercise. He now holds 145,435 shares. Vaxcyte's OPUS-1 trial succeeded, with analysts raising price targets to $125-$146. The stock is down to $71.38 but up 63% over a year.
How this was made
The 30-second read
Why it matters
The insider transaction adds a fresh data point for traders assessing short‑term sentiment, but the broader catalyst remains the ongoing trial progress.
Market read
Primary relevance stems from the new Form 4 insider sale, offering a modest trading signal.
What to watch
The sale was executed under a pre‑arranged 10b5‑1 plan, which may reduce the informational value of the trade.
Background
Vaxcyte (NASDAQ:PCVX) is a biotech developing the VAX‑31 vaccine; recent analyst upgrades and trial updates have been highlighted.
Ticker impact
Executive EVP/COO Jim Wassil sold 18,000 shares for $1.56M under a 10b5‑1 plan and bought the same number of shares via options, a new Form 4 filing.
likely modest downward pressure as the market prices the insider sell
Form 4 disclosures of executive sales often prompt short‑term selling pressure, especially when the sale size is notable relative to insider holdings.
Market effects
Limited; the sale is company‑specific and does not affect the broader biotech sector.
None; impact confined to Vaxcyte investors.
Low; no broader market implications.
Counterpoint
The buy side of the transaction (option exercise) may indicate confidence, offsetting the sell pressure.
Key entities
- executiveJim Wassil
Executive Vice President, Chief Scientific Officer and COO of Vaxcyte
